Skip to main content

The Kim Lab – where genomics meets cancer biology

We are focused on understanding the genetic events involved in the initiation and progression of renal cell carcinoma (RCC) and bladder cancer as well as how they affect the tumor immune microenvironment. Leveraging NextGeneration sequencing (NGS) of primary human tumors and the faithfulness of genetically engineered murine (GEM) models our goal is to identify the critical genomic changes that are drivers of RCC and bladder cancer with an eye towards identifying therapeutic vulnerabilities.

We are a highly collaborative and multidisciplinary group that believes in team science and are committed to diversity, equity, and inclusion in science and medicine.


Group photo of Kim Lab members

Never be ashamed of trying. Effortlessness is a myth. The people who wanted it the least were the ones I wanted to date and be friends with in high school. The people who want it the most are the people I now hire to work for my company.

Taylor Swift



William (Billy) Kim

About the PI

William Y. Kim, MD, is the Rush S. Dickson Distinguished Professor of Medicine, Genetics, and Pharmacology at UNC-Chapel Hill and is a laboratory-based physician-scientist.

Dr. Kim is part of the Urologic Oncology Program and cares for patients with genitourinary malignancies.

Dr. Kim is the Director of UNC Lineberger’s Precision Oncology Program, co-Leader of the Cancer Genetics Program, and is the co-Director of UNC’s Mouse Phase 1 Unit (MP1U).


Kim Lab Research